Newsstand | Page 21 | Aplastic Anemia and MDS International Foundation

Newsstand

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Prediction of outcomes after allogeneic stem cell transplantation for myelodysplastic syndromes

Originally Published: 09/27/2012
Allogeneic bone marrow transplantation (aBMT; i.e., a bone marrow transplantation whereby the donor is not genetically related to the recipient) is still the only potential cure for MDS patients.  However, an aBMT may cause serious complications, some of which may result in death.  In other cases, MDS will come back.  The aim of this study was to identify patient characteristics that would predict survival in MDS patients after an aBMT. A retrospective study (i.e., a study in which patient’s disease characteristics and history are investigated going back in time) showed that of the many...

Therapy-related Myelodysplastic Syndrome: an analysis of 5 risk models in patients treated with azacitidine

Originally Published: 09/27/2012
Myelodysplastic syndrome (MDS) is a disease mostly associated with old age, however, it can also occur as a complication of anti-cancer treatment, including certain chemotherapies and/or radiation.  This is called therapy-related MDS (t-MDS).  When it happens it is often an aggressive disease and difficult to treat.  MDS is a very heterogeneous group of diseases and to determine what the best treatment option is for a particular patient is challenging.  Doctors are helped in this process by scoring systems that, based on the characteristics of the patient’s disease, help evaluate the...

Specialized technique effective in identifying chromosomal abnormalities, improving prognosis for MDS

Originally Published: 07/31/2012
Note: This abstract was presented at the 2012 ASCO annual meeting in June 2012. The full abstract may be reviewed on the ASCO Annual Meeting Web site. Use the abstract number to access the full report. Abstract # 6521 To date, the most widely used prognostic classification system for myelodysplastic syndrome (MDS) is the International Prognostic Scoring System (IPSS). The first IPSS was derived from a study published in 1997. The IPSS separates patients into four distinct subgroups based solely on the percentage of bone marrow blasts, cytogenetics (branch of genetics which studies the...

Sapacitibine shows promise for high-risk MDS patients

Originally Published: 07/30/2012
Note: This abstract was presented at the 2012 ASCO annual meeting in June 2012. The full abstract may be reviewed on the ASCO Annual Meeting Web site. Use the abstract number to access the full report. Abstract # 6520 Myelodysplastic syndrome (MDS) is a heterogeneous disease, with varied options for treatment. These range from supportive care, which includes blood product transfusions and the use of growth factors, to intensive therapy with allogeneic hematopoietic stem cell transplantation (HSCT). Treatment selection should be based on the patient’s age, performance status, and...

European Study of Horse ATG vs. Rabbit ATG for Treatment of Aplastic Anemia

Originally Published: 07/03/2012
Aplastic anemia is a blood disease caused by the destruction of a person’s normal bone marrow cells by specific white blood cells known as T-lymphocytes. One of the treatment options is to give the patient medications that suppress the immune system, specifically the T-lymphocytes. The best immunosuppressive therapy for patients with severe aplastic anemia (sAA) is a combination of anti-thymocyte globulin (ATG) and cyclosporine (CsA). Combining these two drugs results in response rates of 60-75%. Two types of ATG are currently available.  One derived from the horse, known as horse ATG (hATG...

Overview of stem cell transplantation for aplastic anemia

Originally Published: 07/03/2012
Patients with newly diagnosed severe aplastic anemia (sAA) are treated with drugs that suppress the immune system, antithymocyte globulin (ATG) plus cyclosporine (CsA), or an allogeneic hematopoietic stem cell transplantation (Allo-HSCT).  An Allo-HSCT is a type of bone marrow transplant that uses stem cells taken from another person, known as the donor source or source of the graft. The donor can be the patient’s brother or sister.  This is called a “matched sibling or related donor”.  If a patient does not have a matched sibling or related donor, an unrelated individual that shares...

Allogenic stem cell transplantation for older patients with AML and MDS

Originally Published: 06/29/2012
Note: This abstract was presented at the 2012 ASCO annual meeting in June 2012. The full abstract may be reviewed on the ASCO Annual Meeting Web site. Use the abstract number to access the full report. Abstract # 6529 Myelodysplastic syndrome (MDS) is often a disease of advanced age with a majority of patients over the age of 65 years at the time of their diagnosis. Although some patients with MDS enjoy a long period of time with minimal symptoms or change in their disease, some patients experience a rapid progression to either bone marrow failure or acute myeloid leukemia (AML). For...

Effectiveness of lenalidomide in patients over 75 vs. patients under 75 with RBC transfusion-dependent low/int-1-risk MDS and del5q

Originally Published: 06/29/2012
Note: This abstract was presented at the 2012 ASCO annual meeting in June 2012. The full abstract may be reviewed on the ASCO Annual Meeting Web site. Use the abstract number to access the full report. Abstract # 6522 The FDA approved lenalidomide in 2005 for treatment of lower risk MDS patients (low or intermediate-1 risk IPSS score) with deletion 5q abnormalities who are dependent on red blood cell (RBC) transfusions.  This approval was based on the results of the MDS-003 study, which showed that a majority of such patients who were treated with lenalidomide achieved sustained...

Factors affecting response to treatment for secondary MDS and AML

Originally Published: 06/29/2012
Note: This abstract was presented at the 2012 ASCO annual meeting in June 2012. The full abstract may be reviewed on the ASCO Annual Meeting Web site. Use the abstract number to access the full report. Abstract # 6603 Secondary or t-MDS It is important to recognize that, while secondary MDS (t-MDS) represents approximately 10% of MDS cases, the chance of developing MDS if you are treated for another cancer is very low - less than 1/2 of 1% (0.5%) in most cases, though the risk increases in patients who receive multiple rounds of chemotherapy and radiation therapy, and also in those who...

Risk of developing MDS and AML after radiation treatment for breast cancer

Originally Published: 06/29/2012
Note: This abstract was presented at the 2012 ASCO annual meeting in June 2012. The full abstract may be reviewed on the ASCO Annual Meeting Web site. Use the abstract number to access the full report. Abstract # 6560 Secondary or t-MDS It is important to recognize that, while secondary MDS (t-MDS) represents approximately 10% of MDS cases, the chance of developing MDS if you are treated for another cancer is very low - less than 1/2 of 1% (0.5%) in most cases, though the risk increases in patients who receive multiple rounds of chemotherapy and radiation therapy, and also in those who...